Prialt Sales Sluggish, But Elan Expects Rapid Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Additional audiences for the pain product are being targeted following a "quiet" launch at the beginning of the year.
You may also be interested in...
Merck Signs On For Neuromed’s Chronic Pain Agent
Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.
Merck Signs On For Neuromed’s Chronic Pain Agent
Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.
Elan Maxipime Shortage Due To Manufacturing Suspension
Maxipime manufacturer Bristol-Myers Squibb says it temporarily stopped manufacturing cefepime in January due to documentation issues related to bulk manufacturing. FDA accepts Bristol request to release additional product under an amended filing April 12, Bristol says.